BR112021005775A2 - usos terapêuticos de clusters quânticos atômicos - Google Patents

usos terapêuticos de clusters quânticos atômicos Download PDF

Info

Publication number
BR112021005775A2
BR112021005775A2 BR112021005775-7A BR112021005775A BR112021005775A2 BR 112021005775 A2 BR112021005775 A2 BR 112021005775A2 BR 112021005775 A BR112021005775 A BR 112021005775A BR 112021005775 A2 BR112021005775 A2 BR 112021005775A2
Authority
BR
Brazil
Prior art keywords
composition
aqcs
fact
metal atoms
cells
Prior art date
Application number
BR112021005775-7A
Other languages
English (en)
Portuguese (pt)
Inventor
David Buceta Fernández
Fernando Domínguez Puente
Manuel Arturo López Quintela
Original Assignee
Nanogap Sub-Nm-Powder, S.A.
Universidade De Santiago De Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogap Sub-Nm-Powder, S.A., Universidade De Santiago De Compostela filed Critical Nanogap Sub-Nm-Powder, S.A.
Publication of BR112021005775A2 publication Critical patent/BR112021005775A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021005775-7A 2018-09-26 2019-09-25 usos terapêuticos de clusters quânticos atômicos BR112021005775A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18196959 2018-09-26
EP18196963 2018-09-26
EP18196959.3 2018-09-26
EP18196963.5 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Publications (1)

Publication Number Publication Date
BR112021005775A2 true BR112021005775A2 (pt) 2021-06-29

Family

ID=68342935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005775-7A BR112021005775A2 (pt) 2018-09-26 2019-09-25 usos terapêuticos de clusters quânticos atômicos

Country Status (11)

Country Link
US (1) US20220031740A1 (https=)
EP (1) EP3862109A2 (https=)
JP (2) JP2022502450A (https=)
KR (1) KR20210086606A (https=)
CN (2) CN113179632A (https=)
AU (2) AU2019349780B2 (https=)
BR (1) BR112021005775A2 (https=)
CA (1) CA3111915A1 (https=)
IL (1) IL281663A (https=)
MX (1) MX2021003566A (https=)
WO (1) WO2020065115A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
KR102927722B1 (ko) * 2020-05-09 2026-02-19 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277531B2 (es) * 2005-08-03 2008-07-16 Universidad De Santiago De Compostela Procedimiento para la obtencion de clusteres cuanticos atomicos.
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR20210021306A (ko) * 2018-06-12 2021-02-25 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Also Published As

Publication number Publication date
MX2021003566A (es) 2021-08-16
AU2025238114A1 (en) 2025-10-23
WO2020065115A2 (es) 2020-04-02
EP3862109A2 (en) 2021-08-11
CN113179632A (zh) 2021-07-27
AU2019349780A1 (en) 2021-03-25
WO2020065115A3 (es) 2020-05-22
US20220031740A1 (en) 2022-02-03
AU2019349780B2 (en) 2025-07-03
CA3111915A1 (en) 2020-04-02
JP2022502450A (ja) 2022-01-11
JP2024122998A (ja) 2024-09-10
CN120053481A (zh) 2025-05-30
IL281663A (en) 2021-05-31
KR20210086606A (ko) 2021-07-08

Similar Documents

Publication Publication Date Title
JP2024122998A (ja) 原子量子クラスターの治療的使用
ES2437841T3 (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celular de células de mieloma, o angiogénesis
US11026914B2 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
HK1208365A1 (en) Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
ES2853973T3 (es) Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
US20090054720A1 (en) Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
ES2307867T3 (es) Preparacion combinada que comprende un derivado de morfolinil antraciclina y un inhibidor de topoisomerasa ii.
US20220265592A1 (en) Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US7803350B2 (en) Radioactive arsenic-containing compounds and their uses in the treatment of tumors
US20060078494A1 (en) Use of inhibitors of 24-hydroxylase in the treatment of cancer
US6689811B2 (en) Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers
US20170119895A1 (en) Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
US20070117784A1 (en) Treatment of hyperproliferative diseases with anthraquinones
HK40057518A (en) Therapeutic uses of atomic quantum clusters
Wang et al. Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum
US20260084978A1 (en) Process for producing atomic quantum clusters derivatives
ES2399142T3 (es) Inhibidores marcados con 11C de glucógeno sintasa quinasa-3
EP1477174B1 (en) Radioactive arsenic-containing compounds and their uses in the treatment of tumors
US20240197711A1 (en) Combination Therapy for Cancer Treatment
WO2026036187A1 (en) Methods of treating cns cancers
ES2930009T3 (es) Métodos para el cáncer e inmunoterapia con análogos de glutamina, comprendiendo deoxinivalenol DON incluido
Fong The potential use of cucurbiturils and cyclodextrins to facilitate delivery and anti-neoplastic potentiation of tirapazamine and cisplatin with concurrent radiotherapy in tumours–A quantum mechanical study
Pastera et al. Docetaxel Labeled with Iodine 131 Radionuclide-a Possible New Anticancer Drug?(The Pilot Study)
Millard Discovery of novel small molecules targeting cancer cell metabolism

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]